hydroxyapatite silica Report issue

Small molecule Experimental
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-]
  • InChIKey: XYJRXVWERLGGKC-UHFFFAOYSA-D
  • Mol. Mass: 502.31
  • ALogP: Missing data
  • ChEMBL Molecule:
    durapatite  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

alveograf | calcium hydroxyapatite | calcium hydroxylapatite | durapatite | hydroxyapatite | hydroxyapatite silica | hydroxylapatite | ossopan | ossopan 200 | ossopan 800 | periograf | win-40350

Organizations (19)

Research & Development (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (1)


 

Bone Diseases

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Alveolar Ridge Augmentation (Phase 3)

Bone Regeneration ()

Cellulite (Phase 1)

Chronic Periodontitis (Phase 2)

Deficiency Diseases (Phase 4)

Dental Prosthesis (Phase 2/Phase 3)

Fractures, Bone (Phase 1)

Nerve Sheath Neoplasms (Phase 4)

Periodontal Diseases (Phase 4)

Pulpitis (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial Organizations: 19

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue